About: Immune competence after alemtuzumab treatment of multiple sclerosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immune competence after alemtuzumab treatment of multiple sclerosis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 07 August 2013

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2013 (ast) наукова стаття, опублікована в серпні 2013 (uk) مقالة علمية نشرت في 07 أغسطس 2013 (ar) scientific article published on 07 August 2013 (en)
publication date	wds:Q37451106-54CCBC51-43E2-4CC2-AC03-86E7606A0E4A
publication date	2013-08-07 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37451106-6D493020-E649-499D-9947-656AA194A5C3
language of work or name	English
cites work	wds:Q37451106-04134CD1-8852-432A-9F34-8248CE328155 wds:Q37451106-096DDC16-F47A-419F-A76E-4DB7A36724A1 wds:Q37451106-31C419B7-FCB9-452D-9183-AE28879F95FA wds:Q37451106-6A25ADA1-DC99-4EEB-A781-A618F1DD80E1 wds:Q37451106-84103205-DEAA-4DA1-9E09-36D18F6A272A wds:Q37451106-BBA08DD8-99FA-40C4-A6DF-DC21830F2668 wds:Q37451106-D48EC352-6F6F-41E3-92D6-8EDD15CD9923 wds:Q37451106-E4644B3D-3D07-4104-B2B5-DB1FF1772A99 wds:Q37451106-F217B60C-5282-43CF-87D6-F59A4AF18A5D
cites work	Practice parameter for the diagnosis and management of primary immunodeficiency Alemtuzumab therapy for multiple sclerosis Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls Immunogenicity and reactogenicity to Haemophilus influenzae type B (Hib) conjugate vaccine among rural Alaska adults. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Isotype concentrations of human antibodies to Haemophilus influenzae type b polysaccharide (Hib) in young adults immunized with the polysaccharide as such or conjugated to a protein (diphtheria toxoid) Immunogenicity and safety of PNEUMOVAX II manufactured by a new process in older adults The immunogenicity and safety of a new combined diphtheria, tetanus and poliomyelitis booster vaccine (Td-eIPV)
author name string	wds:Q37451106-8B1E9BD4-84FD-450A-AA0D-C5A332D29C45 wds:Q37451106-A24D662A-7B85-4CDE-8F00-8ABB70C74B8F wds:Q37451106-A29F7BEB-E372-456E-9F0B-51F50BEDA260 wds:Q37451106-B99E677F-81EA-4F6F-B5C4-26996C22E168 wds:Q37451106-D445A6E8-526A-4446-A284-8ECD31D40B4A wds:Q37451106-E9D40EB9-DE2A-446B-B8A4-AB42581D95BC
author name string	Dinakantha S Kumararatne Orla Tuohy D Alastair S Compston Alasdair J Coles Joanne L Jones Claire L McCarthy
rdfs:label	Immune competence after alemtuzumab treatment of multiple sclerosis (en) Immune competence after alemtuzumab treatment of multiple sclerosis (nl) Immune competence after alemtuzumab treatment of multiple sclerosis (ast)
skos:prefLabel	Immune competence after alemtuzumab treatment of multiple sclerosis (en) Immune competence after alemtuzumab treatment of multiple sclerosis (nl) Immune competence after alemtuzumab treatment of multiple sclerosis (ast)
name	Immune competence after alemtuzumab treatment of multiple sclerosis (en) Immune competence after alemtuzumab treatment of multiple sclerosis (nl) Immune competence after alemtuzumab treatment of multiple sclerosis (ast)
title	wds:Q37451106-B8C2EAEC-D942-4FF2-B1D6-F16450D0244D
title	Immune competence after alemtuzumab treatment of multiple sclerosis (en)
page(s)	wds:Q37451106-57548961-3D41-4FA2-9E2C-E9D1B35EC824
page(s)	872-876
instance of	wds:Q37451106-7FB6E02C-B43A-4D44-8A67-4DD94CEF4650
instance of	scholarly article
main subject	wds:Q37451106-54882215-1B34-4805-AF5C-DC26D2BC537F
main subject	multiple sclerosis
PubMed ID	wds:Q37451106-DE3068DD-2B4A-443E-8912-F9E7E1873ADB
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/23925762
PubMed ID	23925762
published in	wds:Q37451106-A9914B15-C848-4BBF-A736-12950218EB56
published in	Neurology
issue	wds:Q37451106-37E84BA7-0F3A-4253-A8B3-C9CD6EF98511
volume	wds:Q37451106-A58F6C6F-6F44-4620-9C70-8B58261E0203
issue	10
volume	81
DOI	wds:Q37451106-83C1A427-F524-4110-889B-6F094361F04F
DOI	http://dx.doi.org/10.1212/WNL.0B013E3182A35215
DOI	10.1212/WNL.0B013E3182A35215
PMCID	wds:Q37451106-B16ED4EC-01D7-4305-BB23-8AF48988AE0F
PMCID	3885219
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37451106
is cites work of	wd:Q28069730 Alemtuzumab for the treatment of multiple sclerosis Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis Vaccines in Multiple Sclerosis Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities Alemtuzumab as Treatment for Multiple Sclerosis. The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies Drug safety evaluation of alemtuzumab for multiple sclerosis

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software